Nusara Thaitawat, AFRIMS, leads a discussion at a pre-conference satellite, *Moving Forward Together: Research Literacy and Community Engagement.*

Delegates discuss conference posters during an evening reception.

Delegates attend a session on pre-clinical and early clinical trials with Susan Zolla-Pazner, NYU.

Jerome Kim, MHRP and Bart Haynes, Duke University, discuss the RV144 correlates analysis with journalists at a press conference.
# Table of Contents

AIDS Vaccine 2011 Overview .................................................................................................................. 1

Attendance ................................................................................................................................................ 2

Program .................................................................................................................................................... 3

Abstracts ................................................................................................................................................... 6

Scholars ....................................................................................................................................................... 7

Media Program .......................................................................................................................................... 8

Partnership Program ................................................................................................................................. 10

Financials .................................................................................................................................................. 11

Appendix .................................................................................................................................................. 12

   I. Committees............................................................................................................................................. 12

   II. Conference Scholars ......................................................................................................................... 16
AIDS Vaccine 2011 Overview

AIDS Vaccine 2011 was hosted by the Global HIV Vaccine Enterprise together with the Faculty of Tropical Medicine at Mahidol University and the Ministry of Public Health of Thailand from 12 to 15 September 2011. The conference, attended by more than 820 researchers, funders, advocates, and policymakers, was the first major HIV vaccine conference to take place in Asia. The region was home to the RV144 study, the first research study to demonstrate that a vaccine could reduce HIV infection risk.

Among the highlights of AIDS Vaccine 2011 was the exciting discussion around the results of the two-year case-controlled studies of RV144. A team of scientific collaborators, led by Jerome Kim and Bart Haynes, reported that they had identified two types of antibodies generated by the immune system that correlated to HIV infection. While it is unclear how these antibodies related with infection risk, the findings help validate the initial efficacy results from RV144 announced in 2009 showing a 31.2% protective effect against HIV, and provide additional information on how to improve immune responses.

The conference also featured hundreds of additional presentations on HIV vaccine basic research and clinical trials, and on long-time and emerging HIV prevention strategies including voluntary medical male circumcision, HIV pre- and post-infection strategies, prevention of mother-to-child transmission, new collaborative partnerships and more. Several discussions focused on current and future strategies for vaccine development, including immunogen design, vector-based HIV vaccines and vaccine adjuvants. The conference closed with a look at novel immunogens and vaccine delivery strategies, the important role of systems biology in identifying the role of different immune components and an analysis of breakthrough viruses, all of which provide valuable insights that may be employed in the design of future vaccine candidates.

At-A-Glance

AIDS Vaccine 2011 engaged a diverse, global community of researchers and advocates in lively debate around the best HIV vaccine research science and the way forward. The conference included:

- 820 participants, representing 45 countries
- 352 abstracts presented (71 oral and 281 posters, including seven oral and 47 poster late-breakers)
- 14 plenary and 34 symposia presentations
- 122 scholarships awarded; five New Investigator Awards presented; 20 complimentary registrations to regional scholars
- Webcasts of plenary sessions, special sessions, opening and closing sessions and press conferences
- Access to presenter slides and posters via the conference website and abstracts via online open access publications
• A coordinated satellite session program featuring five sessions on topics ranging from regulatory issues to research literacy and community engagement to statistical methods in vaccine design
• A coordinated media program featuring an extensive journalist training program, additional educational sessions with journalists and daily press conferences, which helped to secure more than 60 original stories on the conference in media outlets worldwide

Attendance

AIDS Vaccine 2011 was well attended with 820 delegates from 45 countries participating in the conference. These included approximately the same number of participants from Europe and Africa as attended the 2010 conference in Atlanta, nearly three times as many participants from Asia and approximately 150 fewer participants from North America, mostly the US. The strong attendance at AIDS Vaccine 2011 is noteworthy given current restrictions on travel expenses at many organizations and the length of travel required for many conference delegates.

![AIDS Vaccine 2008-2011 Participants by Region](image)

**Fig. 1. AIDS Vaccine 2008-2011 Participants by Region**

Conference attendance included paid registrations (502), conference scholars and regional scholars (147), media registrations (33), invited speakers (45) and registrations for staff, hosts, committee members, and sponsors (93).
Table 1. **Attendance by country of origin**

<table>
<thead>
<tr>
<th>Africa</th>
<th>112</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>2</td>
</tr>
<tr>
<td>Congo</td>
<td>1</td>
</tr>
<tr>
<td>Gambia</td>
<td>1</td>
</tr>
<tr>
<td>Ghana</td>
<td>1</td>
</tr>
<tr>
<td>Kenya</td>
<td>18</td>
</tr>
<tr>
<td>Mali</td>
<td>2</td>
</tr>
<tr>
<td>Mozambique</td>
<td>2</td>
</tr>
<tr>
<td>Nigeria</td>
<td>6</td>
</tr>
<tr>
<td>Rwanda</td>
<td>1</td>
</tr>
<tr>
<td>Senegal</td>
<td>1</td>
</tr>
<tr>
<td>South Africa</td>
<td>52</td>
</tr>
<tr>
<td>Tanzania</td>
<td>11</td>
</tr>
<tr>
<td>Uganda</td>
<td>14</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asia</th>
<th>192</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh</td>
<td>1</td>
</tr>
<tr>
<td>China</td>
<td>36</td>
</tr>
<tr>
<td>India</td>
<td>6</td>
</tr>
<tr>
<td>Indonesia</td>
<td>3</td>
</tr>
<tr>
<td>Israel</td>
<td>1</td>
</tr>
<tr>
<td>Japan</td>
<td>8</td>
</tr>
<tr>
<td>Malaysia</td>
<td>1</td>
</tr>
<tr>
<td>Nepal</td>
<td>1</td>
</tr>
<tr>
<td>Pakistan</td>
<td>1</td>
</tr>
<tr>
<td>Philippines</td>
<td>5</td>
</tr>
<tr>
<td>Taiwan</td>
<td>2</td>
</tr>
<tr>
<td>Thailand</td>
<td>127</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Europe</th>
<th>132</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>7</td>
</tr>
<tr>
<td>Denmark</td>
<td>2</td>
</tr>
<tr>
<td>Finland</td>
<td>2</td>
</tr>
<tr>
<td>France</td>
<td>27</td>
</tr>
<tr>
<td>Germany</td>
<td>9</td>
</tr>
<tr>
<td>Netherlands</td>
<td>12</td>
</tr>
<tr>
<td>Norway</td>
<td>2</td>
</tr>
<tr>
<td>Portugal</td>
<td>1</td>
</tr>
<tr>
<td>Russia</td>
<td>3</td>
</tr>
<tr>
<td>Spain</td>
<td>13</td>
</tr>
<tr>
<td>Sweden</td>
<td>9</td>
</tr>
<tr>
<td>Switzerland</td>
<td>14</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>North America</th>
<th>361</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>24</td>
</tr>
<tr>
<td>United States</td>
<td>337</td>
</tr>
<tr>
<td><strong>Australia</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>Latin America</strong></td>
<td>14</td>
</tr>
<tr>
<td>Argentina</td>
<td>5</td>
</tr>
<tr>
<td>Brazil</td>
<td>8</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>1</td>
</tr>
</tbody>
</table>

The conference made a special effort to attract young and/or early-career investigators. Two hundred eighty-five young and/or early-career investigators attended in the meeting in 2011 vs. 248 in 2010. As in previous years, the Local Host also offered a networking lunch for young and early-career investigators to meet and discuss relevant issues with 34 senior researchers.

**Program**

AIDS Vaccine 2011 included some of the most exciting data reported in the field in recent years. In the midst of what has emerged as the most promising era in HIV prevention research since the AIDS epidemic began, scientists from around the world presented the results of numerous research studies outlining noteworthy advances in the search for a safe and effective HIV vaccine at AIDS Vaccine 2011.

Dr. José Esparza closed the conference noting that “...we were all pretty impressed – both with the breadth and depth of the work presented here, and with the recognition that we are truly in an extraordinary era in HIV prevention research in general, and in HIV vaccine research in particular.”

Notable conference highlights include:

**Clinical studies**

- The first results of the correlates study on RV144 samples, which showed that IgG levels inversely correlated with HIV infection, whereas levels of IgA in plasma correlated with HIV infection. The IgGs were directed at the V1V2 loop of the HIV envelope. (J. Kim PL01.05 and B. Haynes PL01.06)
• An analysis of sequences of breakthrough viruses in the RV144 trial, which did not find a statistically-significant impact of vaccination on the number of incoming viruses or their diversity from the strain used in the vaccine. However, evidence of a sieve effect was observed both in gp120 and V2, with larger V2 loops in vaccines as well as specific sites under selection in that region. These findings lend further support to the role of V2-binding antibodies, proposed based on immunogenicity correlate analysis (M. Rolland, S07.02).

• A presentation on the Vaccine Research Center’s plan to use passive immunization with VRC01, which includes Phase I studies in HIV infected and uninfected adults as well as in uninfected infants, to test the safety and pharmacokinetics of VRC01 administration. A Phase IIb study to assess the effect on protection in infants is scheduled for mid 2013. (B. Graham S04.01)

• Discussions around bridging and sustaining community partners, including ethical recommendations for care in HIV vaccine trials (C. Slack S01.03) and the need to adapt the community engagement agenda to ensure preparedness for today’s challenges. (A. Menezes S01.04)

• A presentation on the analysis of samples collected within days of vaccination in the HVTN 071 study, which showed that within 24 hours, vaccinated volunteers developed uniform signatures of changes in expression and alternative splicing of genes involved in innate responses and T-cell trafficking. These signatures were distinct from those described earlier for yellow-fever vaccination. (A. Aderem, S05.05).

Pre-clinical studies

• Observed protection (30%) against homologous SIVmac251 repeated low-dose challenge, which was similar to that seen in the RV144 trial. The vaccine did not have any effect on viral load or CD4 levels. (G. Franchini, OA01.03)

• The need to incorporate genetics into animal models in order to, among other things, account for the impact of TRIM5 polymorphism in non human primate studies. (W. Johnson S03.05)

• Data showing the results of an Ad26/MVA vaccine trial in macaques, in which several immune responses correlated with protection against acquisition, including Env Elisa, Tier 1 neutralizing antibodies and ADCC. Further data demonstrating that inclusion of the envelope into the vaccine candidate was critical for the observed protection. (D. Barouch, S06.05).

Basic research

• The first crystal structure of the HIV-1 gp120 V1V2-scaffolds, which showed that V1V2 exists as a 4-stranded β-sheet with highly variable loops connecting strands. (J. McLellan OA03.03)

• Research demonstrating how PGT antibodies penetrate the Env glycan shield (I.A. Wilson OA04.05), and the identification of broadly cross-neutralizing antibodies in the CAPRISA cohort that were developed after viral escape by glycan addition. (P. Moore OA04.07)
A presentation on how to rationally guide antibody affinity maturation by designing immunogens that bind to VRC01 germline antibody, which supports the feasibility of developing broadly neutralizing antibodies that need high affinity maturation such as VRC01. (P. Kwong S02.04)

A study looking at 621 patients that found no enrichment of certain HLA class I alleles during acute HIV infection and no association of presence or absence of a CD8 T cell response with lower viral load. (H. Streeck OA05.06)

**Knowledge sharing**

For individuals unable to attend AIDS Vaccine 2011, the conference offered archived webcasts of the opening and closing, plenary and special sessions as well as the daily press conferences to help extend the information and discussion generated by the conference. Webcasts are available by visiting the conference archives.

In addition, conference abstracts were published in an open access issue of *AIDS Research and Human Retroviruses* (Online publication of the abstracts in ARHR can be viewed by visiting the website: [http://www.liebertonline.com/doi/pdfplus/10.1089/aid.2011.1502](http://www.liebertonline.com/doi/pdfplus/10.1089/aid.2011.1502)) and an open access archive of slides and posters presented was made available (presenters were encouraged to share their slides and posters, with the option of blacking out confidential information).

**Satellites**

Each year the conference hosts educational satellite events sponsored by research and community-based organizations around the world. AIDS Vaccine 2011 hosted five satellite sessions on 11 and 12 September prior to the opening of the conference. Satellite sessions included:

- The Enterprise OCTAVE workshop on statistical method in HIV trial design and evaluation;
- An update from the African AIDS Vaccine Partnership (AAVP);
- A symposium on critical regulatory issues in AIDS vaccine research organized by the Government of Canada, WHO and the Enterprise;
- A session on research literacy and community engagement organized by Thai NGO Coalition on AIDS (TNCA), AVAC, HVTN, IAVI, UNAIDS, and the US MHRP;
- Best practices on gathering sexual risk information in HIV biomedical prevention trials organized by USAID, IAVI, UNAIDS, US MHRP, VRC/NIAID, PHRU, Mahidol University and DAIDS/NIAID.
Abstracts

AIDS Vaccine 2011 received 384 abstract submissions during the regular submission time and 55 additional abstracts as late-breakers. Of the 384 regular and 55 late-breaker abstract submissions:

- 64 regular and seven late-breaker abstracts were selected for oral presentation in 11 oral abstract sessions
- 234 regular and 47 late-breaker abstracts were selected for poster presentation
- 29 were rejected
- 58 abstracts were withdrawn

A comparison of abstract submission numbers by topic for 2010 and 2011 is shown in the table below.

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>2010</th>
<th>2011</th>
<th>2010</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Regular</td>
<td>Late-breaker</td>
<td>Regular</td>
<td>Late-breaker</td>
</tr>
<tr>
<td>Acute HIV Infection</td>
<td>15</td>
<td>-</td>
<td>16</td>
<td>-</td>
</tr>
<tr>
<td>Adjuvants</td>
<td>10</td>
<td>2</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Animal Models</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>B Cell Immunology and Neutralizing Antibodies</td>
<td>61</td>
<td>16</td>
<td>51</td>
<td>11</td>
</tr>
<tr>
<td>B Cell Vaccine Concepts and Design</td>
<td>17</td>
<td>3</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Clinical Trial Site Challenges</td>
<td>18</td>
<td>1</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>Host Genetic Factors</td>
<td>9</td>
<td>1</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Immune Escape</td>
<td>14</td>
<td>1</td>
<td>10</td>
<td>-</td>
</tr>
<tr>
<td>Innate Immunity</td>
<td>18</td>
<td>3</td>
<td>25</td>
<td>-</td>
</tr>
<tr>
<td>Mucosal Immunity</td>
<td>20</td>
<td>1</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>Novel Immunogens/Inserts</td>
<td>9</td>
<td>1</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Pediatric/Adolescent Infections &amp; Trials</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Preclinical &amp; Clinical Therapeutic Trials</td>
<td>8</td>
<td>1</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Preclinical and Clinical Prophylactic Vaccine Trials</td>
<td>23</td>
<td>3</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>Prevention Strategies</td>
<td>25</td>
<td>2</td>
<td>25</td>
<td>2</td>
</tr>
<tr>
<td>Social/Ethical/Access/Regulatory Issues</td>
<td>44</td>
<td>-</td>
<td>24</td>
<td>6</td>
</tr>
<tr>
<td>T Cell Immunity</td>
<td>29</td>
<td>5</td>
<td>39</td>
<td>-</td>
</tr>
<tr>
<td>T Cell Vaccine Concepts &amp; Design</td>
<td>18</td>
<td>4</td>
<td>27</td>
<td>8</td>
</tr>
<tr>
<td>Vaccine Concepts &amp; Design</td>
<td>66</td>
<td>5</td>
<td>39</td>
<td>4</td>
</tr>
<tr>
<td>Viral Diversity</td>
<td>12</td>
<td>2</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Virology &amp; Immunology of HIV Transmission</td>
<td>19</td>
<td>2</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>TOTAL</td>
<td>445</td>
<td>53</td>
<td>384</td>
<td>55</td>
</tr>
</tbody>
</table>

Table 2. Regular and late-breaker abstract submission numbers by topic - 2010 and 2011
To qualify as a late-breaker abstract, the abstract must contain novel data not available at the time of the original abstract submission deadline.

All submitted abstracts were assigned to six independent reviewers for evaluation. A total of 76 highly respected individuals in the field assisted in the abstract review process.

An abstract was considered for rejection if:

- It was poorly written or confusing
- The study was too preliminary or didn’t contain new information
- Data and/or methods were inadequate to support conclusions or there was insufficient sample size
- Controls, statistical evaluation, and/or summary of essential results were inadequate or missing
- The topic was not appropriate for AIDS Vaccine 2011

Scholars

Conference Scholarships

The annual AIDS Vaccine conference offers approximately 120 full scholarships and five new investigator awards each year to enable greater participation of researchers and students who may not otherwise be able to attend the meeting. In 2011, the conference received 280 scholarship applications for 122 available slots. To be considered for a scholarship, applicants must submit a statement describing their career interests, reasons for attending the conference and need for financial assistance. Preference is given to applicants who are presenting work at the conference. A total of 122 conference scholarships and five new investigator awards were presented.

<table>
<thead>
<tr>
<th>Conference Scholarships</th>
<th>Africa</th>
<th>Asia</th>
<th>Europe</th>
<th>North America</th>
<th>Australia</th>
<th>South America</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applications</td>
<td>103</td>
<td>40</td>
<td>31</td>
<td>78</td>
<td>2</td>
<td>19</td>
</tr>
<tr>
<td>Awarded</td>
<td>26</td>
<td>14</td>
<td>20</td>
<td>50</td>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>

Table 3. Overview of conference scholarship applications

Complimentary Registration Scholarships

In addition to conference scholarships, AIDS Vaccine 2011 provided 20 complimentary registrations to local scholars. Mahidol University provided additional full scholarships for six attendees from Asia and nine registration scholarships for local Thai scholars.
Media Program

The AIDS Vaccine 2011 media program was led by the Secretariat of the Global HIV Vaccine Enterprise with support from Mahidol University and stakeholders of the Global HIV Vaccine Enterprise. The media program highlighted the exceptional progress in the field of HIV vaccine research illustrated by key findings presented at the meeting. The conference garnered more than 60 original stories worldwide. Those stories consistently communicated accurate, well-informed and appropriately optimistic analyses of HIV vaccine research.

Building on the success of the AIDS Vaccine 2009 and 2010 media programs, the communications team developed a conference media program that included:

- The third annual **Journalist-2-Journalist scholarship program**, a two-day, in-depth pre-conference training for journalist scholars that featured presentations from leading vaccine researchers, educators and Enterprise partners, developed in collaboration with the National Press Foundation (see below)
- Daily press conferences featuring the key research highlights of each conference day
- Webcasts of the press conferences
- A fully operational media center, with staff support to assist journalists in reaching key experts for their stories
- A press kit containing background information on the state of HIV vaccine research, the conference, data presented and key highlights
- Targeted media outreach in advance, during and after the conference
- A tour of Mahidol University and Bangkok for journalist scholars

A total of 39 journalists, including 20 journalist scholars, registered to attend AIDS Vaccine 2011.

**AIDS Vaccine 2011 Journalist-2-Journalist Program**

The Enterprise, in collaboration with the National Press Foundation for a third year, awarded 20 journalists from 16 countries scholarships to attend AIDS Vaccine 2011 and participate in two days of intensive background sessions on HIV vaccine research. These trainings help to secure coverage, increase the visibility of the conference and build a growing global network of journalists prepared to report accurately on HIV vaccine research developments. The 2011 agenda can be found [here](#) and included sessions led by Catherine Hankins, UNAIDS; Jerome Kim, MHRP; Rick King, IAVI; Katharine Kripke, NIAID; Steve Wakefield, HVTN and others.

Journalist scholars were selected from a pool of approximately 200 applicants and were chosen based on their experience in and commitment to covering the scientific, social, and societal aspects of HIV/AIDS. All applicants submitted a cover letter, biography, letter of recommendation from their editor, and two samples of published work relating to HIV/AIDS. Scholars from 2011 represented news outlets around the world including, the British

Resources from the sessions, including audio and PowerPoint presentations by speakers, stories filed by the journalist scholars and other information are available on the National Press Foundation’s web site.

**Daily Press Conferences**

The Secretariat organized three press conferences featuring key research presented at the meeting for the larger audience of health and medical professionals, as well as the general public. These briefings, together with the scientific and community presentations throughout the conference, helped to inform quality media coverage of our shared effort to develop a safe and effective HIV vaccine. The full press program can be found here.

**Media Center**

For the third year, the conference offered a fully operational media center for working journalists. The center was staffed by the Enterprise Secretariat and by volunteers from Mahidol University, who assisted reporters in information gathering and interview arrangements with speakers. The media center also offered laptops, printers and other resources to help reporters develop and file their reports from the conference.

**Press Kit**

The communications team compiled a press kit containing background information on the state of the field, the conference and key meeting highlights. This included an opening press release with quotes from the opening session speakers. All information was provided to the 39 journalists who registered to attend the meeting.
Partnership Program

The success of the AIDS Vaccine conference is due in large part to the generosity of our funding partners. Their contributions keep registration affordable, ensure that the Conference is accessible to individuals from across the globe, and make Conference scholarships possible.

<table>
<thead>
<tr>
<th>Partner Institution</th>
<th>$ USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Glaser Pediatric AIDS Foundation</td>
<td>7,500</td>
</tr>
<tr>
<td>French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</td>
<td>42,757</td>
</tr>
<tr>
<td>GeoVax Labs, Inc.</td>
<td>1,000</td>
</tr>
<tr>
<td>GlaxoSmithKline Biologicals (GSK)</td>
<td>7,132</td>
</tr>
<tr>
<td>Government of Canada</td>
<td>104,090</td>
</tr>
<tr>
<td>International AIDS Vaccine Initiative (IAVI)</td>
<td>15,000</td>
</tr>
<tr>
<td>Mabtech</td>
<td>3,000</td>
</tr>
<tr>
<td>National Institute of Allergy and Infectious Diseases (NIAID)</td>
<td>100,000</td>
</tr>
<tr>
<td>Office of AIDS Research, NIH</td>
<td>400,000</td>
</tr>
<tr>
<td>sanofi Pasteur</td>
<td>13,057</td>
</tr>
<tr>
<td>The Bill &amp; Melinda Gates Foundation</td>
<td>300,000</td>
</tr>
<tr>
<td>U.S. Military HIV Research Program (MHRP)</td>
<td>50,000</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>25,000</td>
</tr>
<tr>
<td>Wellcome Trust</td>
<td>22,550</td>
</tr>
<tr>
<td>Xstrata - Global Diversified Mining Group</td>
<td>30,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$1,121,086</strong></td>
</tr>
</tbody>
</table>

Table 4 Overview of AIDS Vaccine 2011 Partners
## Financials

### Income

<table>
<thead>
<tr>
<th>Description</th>
<th>$ USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>301,090</td>
</tr>
<tr>
<td>Sponsor Income and Grants</td>
<td>1,147,515</td>
</tr>
<tr>
<td>In-kind Sponsorships</td>
<td>45,567</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>$1,494,172</strong></td>
</tr>
</tbody>
</table>

### Expense

<table>
<thead>
<tr>
<th>Description</th>
<th>$ USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional Fees – Communications</td>
<td>41,997</td>
</tr>
<tr>
<td>Professional Fees – Scientific</td>
<td>139,444</td>
</tr>
<tr>
<td>Meeting Facility Costs</td>
<td>49,580</td>
</tr>
<tr>
<td>Presentation Costs</td>
<td>126,091</td>
</tr>
<tr>
<td>Media Relations/ Marketing Materials</td>
<td>12,797</td>
</tr>
<tr>
<td>Participant Lodging (Speakers and Scholarship Recipients)</td>
<td>158,004</td>
</tr>
<tr>
<td>Participant Transportation</td>
<td>11,048</td>
</tr>
<tr>
<td>Participant Meals &amp; Incidentals</td>
<td>242,047</td>
</tr>
<tr>
<td>Participant Airfare (Speakers and Scholarship Recipients)</td>
<td>358,445</td>
</tr>
<tr>
<td>Participant Other</td>
<td>66,491</td>
</tr>
<tr>
<td>Registration Other</td>
<td>45,498</td>
</tr>
<tr>
<td>Publications</td>
<td>64,680</td>
</tr>
<tr>
<td>Supplies &amp; Other Expenses</td>
<td>49,515</td>
</tr>
<tr>
<td>In-kind Expense</td>
<td>45,567</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td><strong>$1,411,204</strong></td>
</tr>
</tbody>
</table>
Appendix

I. Committees

AIDS Vaccine Steering Group

Galit Alter  
Ragon Institute of MGH, MIT and Harvard, USA

Dan Barouch  
Beth Israel Deaconess Medical Center, USA

Alan Bernstein  
Global HIV Vaccine Enterprise, USA

José Esparza  
The Bill & Melinda Gates Foundation, USA

Catherine Hanks  
Joint United Nations Programme on HIV/AIDS (UNAIDS), Switzerland

Barton Haynes  
Human Vaccine Institute, Duke University, USA

Eric Hunter  
Center for AIDS Research, Emory University, USA

Pontiano Kaleebu  
Uganda Virus Research Institute, Uganda

Katharine Kripke  
National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA

Yves Levy  
French National Agency for Research on AIDS and Viral Hepatitis, France

Siobhan Malone  
The Bill & Melinda Gates Foundation, USA

Bonnie Mathieson  
Office of AIDS Research National Institutes of Health, USA

Margaret McCluskey  
United States Agency for International Development, USA

Howard Njoo  
Public Health Agency of Canada, Canada

Punnee Pitisuttithum  
Faculty of Tropical Medicine, Mahidol University, Thailand

Rino Rappuoli  
Novartis, Italy

Pratap Singhasivanon  
Mahidol University, Thailand

Steve Wakefield  
HIV Vaccine Trials Network, USA

AIDS Vaccine 2011 Conference Chair

Pratap Singhasivanon  
Faculty of Tropical Medicine, Mahidol University, Thailand

Conference Co-chairs

Punnee Pitisuttithum  
Faculty of Tropical Medicine, Mahidol University, Thailand

Manit Teeratantikanont  
Department of Disease Control, Ministry of Public Health, Thailand

Local Organizing Committee

Somsak Akksilp  
Ministry of Public Health, Thailand

Supachart Bandhumani  
Immigration Bureau of Thailand, Thailand

Chamaiporn Bumrungsin  
Landside Operations Department, Suvarnabhumi Airport, Airports of Thailand Public Company Limited (AOT), Thailand

Thanaporn Chaibongsai  
Thai Airways International Public Company Limited, Thailand

Panada Chanitwat  
Thai Airways International Public Company Limited, Thailand

Vichai Chokevivat  
Government Pharmaceutical Organization (GPO), Thailand

Kachit Choopanya  
Bangkok Tenofovir Study Group (BTSG), Bangkok Metropolitan Administration (BMA), Thailand

Supamit Chunsuttiwat  
Ministry of Public Health, Thailand
Pokrath Hansasuta  Faculty of Medicine, Chulalongkorn University, Thailand
Tamashiro Hiko  Graduate School of Medicine, Department of Global Health and Epidemiology (GHE), Hokkaido University, Japan
Amorn Leelarasamee  Division of Infectious Disease and Tropical Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Supraba Moleeratanond  Thailand Convention and Exhibition Bureau, Thailand
Viseth Ngauy  Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand
Sorachai Nitayaphan  Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand
Charles Pamonmontri  Ministry of Public Health, Thailand
Praphan Panuphak  Thai Red Cross AIDS Research Centre, Thailand
Yaowapa Pratoomsuwan  Faculty of Tropical Medicine, Mahidol University, Thailand
Sasithon Pukrittayakamee  Faculty of Tropical Medicine, Mahidol University, Thailand
Supachai Rerks-Ngarm  CDC Department, Ministry of Public Health, Thailand
Kiat Ruxrungtham  Division of Allergy and Clinical Immunology, Faculty of Medicine, Chulalongkorn University, Thailand
Thira Sirisanthana  Research Institute for Health Sciences, Chiang Mai University, Thailand
Sugree Sithivanich  Tourism Authority of Thailand (TAT), Thailand
Vichaya Soonthornsaratoon  Thailand Convention and Exhibition Bureau, Thailand
Ruengpung Sutthent  Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand
Thitika Teeranetr  Faculty of Tropical Medicine, Mahidol University, Thailand
Prasert Thongcharoen  Virology Association, Thailand
Sirisak Warintarawat  Ministry of Public Health, Thailand
Chantapong Wasi  Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand

Scientific Coordinator
Srisin Khusmith  Faculty of Tropical Medicine, Mahidol University, Thailand

Communications and Media Relations Coordinator
Kasinee Buchachart  Faculty of Tropical Medicine, Mahidol University, Thailand

Logistics Coordinator
Jitra Waikagul  Faculty of Tropical Medicine, Mahidol University, Thailand

Secretary to the Local Organizing Committee
Paul Adams  Faculty of Tropical Medicine, Mahidol University, Thailand

Assistant Secretary to the Local Organizing Committee
Pornpimon Adams  Faculty of Tropical Medicine, Mahidol University, Thailand
Consultants to the Local Organizing Committee

Piyasvasti Amranand Thai Airways International Public Company Limited, Thailand
Wiboon Bangtamai Commissioner of the Immigration Bureau, Thailand
Ekalarp Rattanaruja Suvarnabhumi Airport Passenger Control Customs Bureau, Thailand
Piyasakol Sakolsatayadorn President, Mahidol University, Thailand
Suraphon Svetasreni Tourism Authority of Thailand (TAT), Thailand
Nirandra Theeranartsin Airports of Thailand Public Company Limited (AOT), Thailand

Scientific Organizing Committee

Galit Alter Ragon Institute of MGH, MIT and Harvard, USA
Viktor Appay French National Institute of Health and Medical Research (INSERM), France
Susan Barnett Novartis Vaccines and Diagnostics, Inc., USA
Dan Barouch Beth Israel Deaconess Medical Center, USA
Alan Bernstein Global HIV Vaccine Enterprise, USA
Susan Buchbinder San Francisco Department of Public Health, USA
Damien Chaussabel Baylor Institute for Immunology Research, USA
Daniel Douek Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA
Jacques Fellay Federal Institute of Technology (EPFL), Switzerland
Keith Fowke University of Manitoba, Canada
Genoveffa Franchini National Cancer Institute, National Institutes of Health, USA
Barney Graham Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA
Glenda Gray Perinatal HIV Research Unit, South Africa
Catherine Hankins Joint United Nations Programme on HIV/AIDS (UNAIDS), Switzerland
Barton Haynes Human Vaccine Institute, Duke University, USA
Shiu-Lok Hu University of Washington, USA
Margaret Johnston National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA
Stephen Kent University of Melbourne, Australia
Srisin Khusmith Faculty of Tropical Medicine, Mahidol University, Thailand
Jerome Kim Walter Reed Army Institute of Research (WRAIR), USA
Wayne Koff International AIDS Vaccine Initiative (IAVI), USA
Roger Le Grand French Alternative Energies and Atomic Energy Commission (CEA), France
Amapola Manrique Global HIV Vaccine Enterprise, USA
John Mascola Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA
Bonnie Mathieson Office of AIDS Research, National Institutes of Health, USA
Francine McCutchan The Bill & Melinda Gates Foundation, USA
Lynn Morris National Institute for Communicable Diseases, South Africa
Gary Nabel Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, USA
Punnee Pitisuttithum Faculty of Tropical Medicine, Mahidol University, Thailand
Ronald Swanstrom  University of North Carolina, USA  
Jim Tartaglia  sanofi pasteur, USA  
Amalio Telenti  University Hospital and University of Lausanne, Switzerland  
Caroline Tiemessen  National Institute for Communicable Diseases, South Africa  
Georgia Tomaras  Duke University, USA  
Alexandra Trkola  Institute of Medical Virology, University of Zurich, Switzerland  
Yegor Voronin  Global HIV Vaccine Enterprise, USA  
Anna-Lise Williamson  Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa  
Susan Zolla-Pazner  New York University School of Medicine, Veterans Affairs Medical Center, USA  
Michael Zwick  The Scripps Research Institute, USA  

II. Conference Scholars  

New Investigator Awards  

Muhammed Afolabi  Medical Research Council Laboratories, Gambia  
Amy Chung  University of Melbourne, Australia  
Miguel Lacerda  University of Cape Town, South Africa  
Zaza Ndhlovu  Ragon Institute of MGH, MIT and Harvard, USA  
Bin Su  French National Institute of Health and Medical Research (INSERM) U748, Université de Strasbourg, France  

Conference Scholars  

Adedayo Adeyemi  Measure Evaluation, Nigeria  
Hannah Ajoge  Department of Microbiology, Faculty of Science, Ahmadu Bello University, Zaria, Nigeria  
Tomohiro Akahoshi  Center for AIDS Research, Kumamoto University, Japan  
Kabamba Alexandre  National Institute for Communicable Diseases, South Africa  
Rafael Almeida  University of São Paulo, Brazil  
Michael Alpert  Harvard University, USA  
Carmen Alvarez Fernandez  Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Fundació Clínic per a la Recerca Biomèdica (FCRB), Spain  
Erica Andersen-Nissen  University of Washington/Fred Hutchinson Cancer Research Center, USA  
Raiees Andrabi  All India Institute of Medical Sciences, India  
Hodei Arberas Eguiluz  Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Fundació Clínic per a la Recerca Biomèdica (FCRB), Spain  
Panagiotis Athanasopoulos  Royal Holloway University of London, United Kingdom  
Alejandro Balazs  California Institute of Technology, USA  
Dion Benetatos  Desmond Tutu HIV Foundation, South Africa  
Alfred Bere  University of Cape Town, South Africa  
Jinal Bhiman  National Institute for Communicable Diseases, South Africa  
Marina Biedma  French National Institute of Health and Medical Research (INSERM) U748, Université de Strasbourg, France  
James Billingsley  Harvard Medical School, New England Primate Research Center, USA  
Christian Boutwell  Ragon Institute of MGH, MIT and Harvard, USA
Emma Bowles  University of Oxford, United Kingdom
Lea Brandt  Statens Serum Institut, Denmark
Sarah Brinckmann  University of Oxford, United Kingdom
Justine Brown  University of Washington, USA
Chanson Brumme  BC Centre for Excellence in HIV/AIDS, Canada
Olusegun Busari  Federal Medical Centre, Ido-Ekiti, Nigeria
Sun Caijun  Guangzhou Institute of Biomedicine and Health, China
Makhtar Camara  Laboratory of Bacteriology Virology, Aristide Le Dantec University Hospital, Senegal
Ann Carias  Northwestern University, USA
Bimal Chakrabarti  IAVI Neutralizing Antibody Center/The Scripps Research Institute, USA
Stephane Champiat  University of California, San Francisco, France
Rosamund Chapman  University of Cape Town, South Africa
Gerald Chege  University of Cape Town, South Africa
Shivan Chetty  University of Cape Town, South Africa
Fernanda Côrtes  Instituto Oswaldo Cruz/FIOCRUZ, Brazil
Valerie Cortez  University of Washington/Fred Hutchinson Cancer Research Center, USA
Alberto Crespo Guardo  Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)/Fundació Clínica per a la Recerca Biomèdica (FCRB), Spain
Shayesta Dhalla  University of British Columbia, School of Population and Public Health, Canada
Zelda Euler  Academic Medical Center, University of Amsterdam, Netherlands
Juliana Falivene  Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Emilia Falkowska  The Scripps Research Institute, USA
Anne-Laure Flamar  Baylor Institute for Immunology Research, USA
Ana Gervassi  Seattle Biomedical Research Institute, USA
Shari Gordon  National Cancer Institute, National Institutes of Health, USA
Francisco Guenaga  IAVI Neutralizing Antibody Center/The Scripps Research Institute, USA
Xuan He  Chinese Center for Disease Control and Prevention, China
Tomer Hertz  University of Washington/Fred Hutchinson Cancer Research Center, USA
Henoch Hong  Harvard Medical School, USA
Jue Hou  Chinese Center for Disease Control and Prevention, China
Natalie Hutnick  University of Pennsylvania, USA
Rajesh Jacob  Cellular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Cape Town Component, South Africa
Rashmi Jalal  National Cancer Institute at Frederick, USA
Gabriela Junqueira Calazans  Centro de Referência e Treinamento DST/AIDS, Brazil
Yuanxi Kang  AIDS Institute, LKS Faculty of Medicine, The University of Hong Kong, China
Thomas Kerkhof  Academic Medical Center, University of Amsterdam, Netherlands
Freddie Mukasa Kibengo  Medical Research Council/Uganda Virus Research Institute, Uganda
Nichole Klatt  National Institutes of Health/National Institutes of Allergy and Infectious Diseases/Laboratory for Molecular Medicine, USA
Alexander Kliche  University of Regensburg, Germany
Pratima Kunwar  University of Washington, USA
Alexandre Lederle, French National Institute of Health and Medical Research (INSERM) U748, Université de Strasbourg, France
Mopo Radebe Leshwedi, University of KwaZulu Natal, South Africa
Dan Li, Chinese Center for Disease Control and Prevention, China
Hualin Li, Beth Israel Deaconess Medical Center, USA
Yuxing Li, IAVI Neutralizing Antibody Center/The Scripps Research Institute, USA
Lenine Liebenberg, University of Cape Town Medical School, South Africa
Madelene Lindqvist, Ragon Institute of MGH, MIT and Harvard, USA
Cynthia Maeto, Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Alison Mahan, Ragon Institute of MGH, MIT and Harvard, USA
Sharmila Rama Reddy, Emory University, USA
Adi Moseri, Weizmann Institute of Science, Israel
Kim Mous, University of Antwerp, Belgium
Boris Murashev, State Research Institute of Highly Pure Biopreparations, Russian Federation
Megan Murphy, Emory University, USA
Karuppiah Muthumani, University of Pennsylvania School of Medicine, USA
Roman Ntare, University of Cape Town, South Africa
Peter Oballah, Makerere University Walter Reed Project, Uganda
Irene Onyango, Kenya AIDS Control Project (University of Nairobi and University of Manitoba), Kenya
Alexandra Ortiz, University of Pennsylvania, USA
Craig Pace, Aaron Diamond AIDS Research Center, USA
Maria de los Angeles Pando, Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Vincent Pavot, Institut de Biologie et Chimie des Protéines, Centre National de la Recherche Scientifique, France
Maria Paximadis, National Institute for Communicable Diseases, South Africa
Anabela Picton, National Institute for Communicable Diseases/University of the Witwatersrand, South Africa
Roger Keith Reeves, Harvard Medical School, New England Primate Research Center, USA
Susan Ribeiro, University of São Paulo, Brazil
Catherine Riou, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa
Raabya Rossenkhan, University of Botswana/Botswana Harvard AIDS Institute Partnership, USA
Jonah Sacha, Oregon Health & Science University, USA
Kotou Sangare, GAIA Vaccine Foundation, Mali
Daniel Sheward, University of Cape Town, South Africa
Simon Sigirenda, Uganda Virus Research Institute, Uganda
Anthony Smith, University of Minnesota, USA
Kellie Smith, University of Pittsburgh School of Medicine, USA
Damien Soghoian, Ragon Institute of MGH, MIT and Harvard, USA
Ali Ssetaala, Uganda Virus Research Institute/IAVI HIV Vaccine Program, Uganda
Kathryn Stephenson, Beth Israel Deaconess Medical Center, USA
Ingemar Sundling, Karolinska Institutet, Sweden
Leandro Tarosso, University of São Paulo, Brazil
Christina Thobakgale  
HIV Pathogenesis Programme, University of KwaZulu-Natal, South Africa

Gabriela Turk  
Argentinean National Reference Center for AIDS, Argentina

Nicolas Vabret  
Institut Pasteur, France

Marit van Gils  
Academic Medical Center, University of Amsterdam, Netherlands

Griet Van Roey  
St George’s, University of London, UK

Sundaram Vishwanathan  
Centers for Disease Control and Prevention, USA

Yanmin Wan  
Shanghai Public Health Clinical Center, China

Yaoyu Wang  
Dana-Farber Cancer Institute, USA

Constantinos Wibmer  
National Institute for Communicable Diseases, South Africa

Leia Wren  
The University of Melbourne, Australia

Tian Xiaoling  
Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, China

Lifei Yang  
Institut Pasteur of Shanghai, Chinese Academy of Science, China

Tingting Yuan  
AIDS Institute, The University of Hong Kong, China

Anli Zhang  
Institutes of Biomedical Sciences, Fudan University, China

Mei-Yun Zhang  
The University of Hong Kong, China

Mingkui Zhou  
Georg-Speyer-Haus Institute for Biomedical Research, Germany